
Product Data Sheet

Product Name: Bunaprolast (U66858)

Cat. No.: GC32002

Chemical Properties

Cas. No. 99107-52-5

SMILES COC1=C2C=CC=CC2=C(OC(C)=O)C(CCCC)=C1

Formula $C_{17}H_{20}O_3$ M.Wt 272.34

Solubility Soluble in DMSO Storage Store at $-20^{\circ}C$

General tips For obtaining a higher solubility, please warm the tube at $37^{\circ}C$ and shake it in the ultrasonic bath for a while. Stock solution can be stored below $-20^{\circ}C$ for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure

Background

Bunaprolast (U66858) is a potent inhibitor of LTB₄ production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of lipoxygenase and TXB₂ release.

Bunaprolast (U-66,858) undergoes deacetylation to an initial metabolite with similar pharmacological potency. The inhibitory effects of the semi-quinone Bunaprolast and its metabolite U-68,244 on the ionophore-induced formation of leukotriene B₄ (LTB₄) are examined in human whole blood (WB). Preincubation of Bunaprolast and U-68,244 for 1 min prior to challenge of blood with calcium ionophore A23187 results in IC₅₀s of 1080 ± 644 and 820 ± 442 nM, respectively. After 60 min preincubation, IC₅₀s are 250 ± 85 and 270 ± 79 nM. The activity of the lipoxygenase inhibitor AA-861 in this system is similar to that of Bunaprolast, while vitamin K and the sulphate conjugate of Bunaprolast show significant inhibition of LTB₄ release only at micromolar concentrations. Bunaprolast exhibits significant inhibition of thromboxane A₂ release (p

The IgE-mediated hypersensitivity to Ascaris antigen in reactor rhesus primates is used to assess the pharmacologic profile of Bunaprolast (U-66,858). When Bunaprolast is

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

given by the oral route, it shows dose-related inhibition of resistance (RL) and compliance (Cdyn) changes. When Bunaprolast is given by the aerosol route, it shows dose independent inhibition. In 15 animals, aerosols (52 ± 32 to $53\pm 10\%$ for RL, $p=0.05$ and 45 ± 19 to $28\pm 19\%$ Cdyn inhibitions, $p=0.05$) for 5.0-0.1% aerosol. By the oral route, inhibition is seen at 1-4 h following administration. In 5 animals, oral doses of 10 and 5 mg/kg inhibit (RL by 98 ± 2 to $78\pm 1.5\%$, $p=0.01$ and Cdyn by 75 ± 17 to $60.9\pm 9.1\%$, $p=0.05$) by 10 and 5 mg/kg Bunaprolast, respectively[2].

[1]. Summers JA, et al. Lipoxygenase inhibitory activity of U-66,858 and its deacetylated metabolite U-68,244 in human whole blood. Agents Actions. 1994 Mar;41(1-2):32-6. [2]. Johnson HG, et al. Activity of a novel hydroquinone inhibitor of leukotriene synthesis (U-66,858) in the rhesus monkey Ascaris reactor. Int Arch Allergy Appl Immunol. 1988;87(2):204-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA